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Background: Penile cancer (PC) is a rare tumor, and therapeutic options are limited for this disease, with an overall
5-year overall survival around 65-70%. Adjuvant therapy is not recommended for patients with N0-1 disease, despite
up to 60% of these patients will die within 5 years from diagnosis.
Methods: Medical records of all patients who underwent radical surgery at University Federico II of Naples and at
National Tumor Institute “Pascale” of Naples for early squamous cell carcinoma of the penis from January, 2000 to
December, 2011 were retrieved. Paraffin wax embedded tissue specimens were retrieved from the pathology
archives of the participating Institutions for all patients. Expression of p-EGFR, EGFR and positivity to HPV were
evaluated along with other histological variables of interest. Demographic data of eligible patients were retrieved
along with clinical characteristics such as type of surgical operation, time of follow up, time of recurrence, overall
survival. A multivariable model was constructed using a forward stepwise selection procedure.
Results: Thirty eligible patients were identified. All patients were positive for EGFR by immunohistochemistry, while
13 and 16 were respectively positive for nuclear and cytosolic p-EGFR. No EGFR amplification was detected by FISH.
Eight patients were positive for high-risk HPV by ISH. On univariable analysis, corpora cavernosa infiltration
(OR 7.8; 95% CI = 0,8 to 75,6; P = 0,039) and positivity for cytosolic p-EGFR (OR 7.6; 95% CI =1.49 to 50; P = 0.009)
were predictive for recurrence, while only positivity for cytosolic p-EGFR (HR =9.0; 95% CI 1.0-100; P = 0,0116) was
prognostic for poor survival.
Conclusion: It is of primary importance to identify patients with N0-1 disease who are at increased risk of
recurrence, as they do not normally receive any adjuvant therapy. Expression of p-EGFR was found in this series to
be strongly related to increase risk of recurrence and shorter overall survival. This finding is consistent with the role
of p-EGFR in other solid malignancies. Integration of p-EGFR with classic prognostic factors and other histology
markers should be pursued to establish optimal adjuvant therapy for N0-1 PC patients.
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Incidence of penile cancer (PC) is around 0,5-1 per 100000
males in Europe and in the United States, climbs to 8.3 per
100 000 in parts of Asia, Africa and South America [1].
Squamous cell carcinoma represents the greatest majority
of PC cases [1]. Therapeutic options are limited for this
disease, with a 5-year overall survival around 65-70%, and
no significant improvement over the past two decades [2].
Prognosis is dismal in patients not amenable to radical
surgery, who generally survive less than 12 months [3].
After surgical removal of the primary tumor, patients with
clinically positive nodes should undergo regional lymph-
adenectomy, while in patients with clinically negative
lymphnodes, nomograms and sentinel-node biopsy are
extremely useful to advice for lymphadenectomy [4].
Adjuvant chemotherapy is recommended in patients
with N2 or N3 lymphnode involvement [4]. Although
node status is the major prognostic determinant in PC, a
significant number of clinical and biological factors of
prognostic value have been identified. A nomogram, in-
cluding growth pattern, histologic grade, lymphatic or
venous embolization, corpora cavernosa and spongiosum
infiltration and pathological regional lymph node in-
volvement showed a concordance index of around 74%
for cancer specific 5-year survival [5]. A number of bio-
logical variables have also proved to have a potential
prognostic role in PC, including HPV [6], periostin [7],
p53 [8], such as ki67, mini-chromosome maintenance 2
protein (MCM2) and geminin [9].
The epidermal growth factor receptor is a member of
the HER/erbB family of receptor tyrosine kinases, which
also includes HER2 (neu, erbB2), HER3 (erbB3), and
HER4 (erbB4) [10]. Ligand binding and dimerization of
EGFR causes autophosphorylation of the intracytoplasmic
domains and activation of the intracellular tyrosine kinase.
EGFR is overexpressed in the majority of PC patients [11].
Nevertheless, in a recent work conducted in 148 PC tissue
samples, the phosphorylated active form of EGFR was
detected in only a fourth of all samples [10]. EGFR phos-
phorylation appeared to be predictive of poor prognosis in
a number of malignancies, including non-small-cell lung
cancer, breast cancer and oropharyngeal cancer [12-14].
The aim of this study was to gain further insight into
the prognostic role of p-EGFR status in early stage PC
patients, which was assessed in a sample of thirty men
after controlling for known prognostic factor in PC
using a multivariable model.
Patients and methods
Patients
Medical records of all patients who underwent radical sur-
gery at University Federico II of Naples and at National
Tumor Institute “Pascale” of Naples for early squamous
cell carcinoma of the penis from January, 2000 toDecember 2011 were retrieved. Patients were required to
have assessment of inguinal lymphnode status via sentinel
node biopsy or lymphadenectomy. Patients with >N1 or
M1 disease or those who received perioperative chemo-
therapy were excluded from this analysis. Demographic
data of eligible patients were retrieved along with clinical
characteristics such as type of surgical operation, time of
follow up, time of recurrence, overall survival. Local
research ethics committee approval for the study was
obtained.
Histology review
Paraffin wax embedded tissue specimens were re-
trieved from the pathology archives of the participating
Institutions for all patients. The lack of fresh tissue
specimens did not affect the quality of the analyses
performed. Excised tumors were histologically staged
using the revised TMN system criteria 2002 [15]. Patho-
logical variables of the primary tumor included: grade,
local stage, subtype, and lymphovascular invasion. Tumor
grade was defined using Broders's classification [16].
Lymphovascular invasion was determined microscopically
and confirmed using antibodies against endothelial mar-
kers CD33 and CD34. Lymph node status at the time of
diagnosis was confirmed following pathological review of
sentinel node biopsy and inguinal nodes specimens
obtained with lymphadenectomy.
TMA building
A Tissue Micro-Array (TMA), has been built using 35 tis-
sue samples, including 30 penile squamous cell carcinoma
(PSCC) and 5 normal tissues. A single block for each case
has been selected for the TMA building, identifying the
most representative tumoral areas from blocks of surgical
samples as well as normal gland tissue where possible. All
tumours and controls have been reviewed by two expe-
rienced pathologists.
Tissue cylinders with a diameter of 1 mm have been
punched from morphologically representative tissue areas
of each ‘donor’ tissue block and brought into one recipient
paraffin block (3 × 2.5 cm) using a semiautomated tissue
arrayer , CK 3500 Tissue Microarrayer; ISE TMA Software
(Galileo TMA, Integrated System Engineering, Milan,
Italy).
Immunohistochemistry analysis
Immunohistochemical analysis has been performed on
4-μm TMA serial sections from formalin-fixed, paraffin
embedded tissues, in order to evaluate the expression of
EGFR (clone 3C6 EGFR Ventana); p-EGFR Tyr 845 (clone
2231 phospho-EGF receptor (Tyr845) Cell signaling).
Negative control slides without primary antibody were
included for each staining.
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rehydrated through graded alchols. Antigen retrieval has
been performed with slides heated in 1 mM EDTA buffer,
pH 8.0 in a bath for 20 min at 97°C. After antigen retrieval,
the slides allow to cool. The slides have been rinsed with
TBS and the endogenous peroxidase has inactivated with
3% hydrogen peroxide. After protein block (BSA 5% in
PBS 1x), every slides have been incubated with specific pri-
mary antibody: anti phospho-EGFR tyr845 (rabbit 1:100
over night). The sections have been rinsed in TBS and
incubated for 20 minutes with Novocastra Biotinylated
Secondary Antibody (RE7103), a biotin-coniugated se-
condary antibody formulation that recognized mouse
and rabbit immunoglobulins. Then the sections have
been rinsed in TBS and incubated for 20 minutes with
Novocastra Streptavidin-HRP (RE7104) and then pero-
xidase reactivity has been visualized using a 3,3’-
diaminobenzidine (DAB). Finally, the sections have been
counterstained with hematoxylin and mounted. Results
are interpreted using a light microscope.
The results of the immunohistochemical staining were
evaluated separately by two observers. In each tissue
section 10 representative high power fields (HPFs) were
analyzed at optical microscope (OLYMPUS BX41, at x40)
and were selected for EGFR positive tumor cells with an
average of 1000 tumor cell per case and 200 tumor cells
per field. The topographical staining pattern was also eva-
luated and recorded as membranous (M), cytoplasmic (C),
or mixed, and nuclear (N). For each case, the cumulative
percentage of positive cells among all sections examined
was determined as follows: 0 points for negative staining
of the considered cells, (1) <10%, (2) 10-50%, (3) 51-80%
and (4) ≥ 80% positive staining of the considered cells.
The intensity of staining was scored as 0, no staining; +,
weak; ++, moderate; +++, strong.
For p-EGFR Tyr 845 and p-EGFR Tyr 1068 immunohis-
tochemical evaluation, we selected a dichotomized indica-
tor variable. We established a cut-off point at 5%: the cells
were considered positive when > 5% of them showed a
cytoplasm staining, and negative when no staining was
observed or < 95% of cells stained for the marker. Intensity
of staining was not scored for p-EGFR [14].
FISH analysis
FISH analysis has been performed on representative sec-
tions of PSCC TMA. The slides were deparaffinized and
hydrated than they were immersed in citrate buffer (ph 6)
for 15 min at 85°C. The slides were then rinsed in distilled
water for 5 min for two times. The slides pre-treatment
and protease incubation were performed according the
manufactures illustrated in datasheet of Vyses (paraffin
pre-treatment reagent kit II).
The probes utilized were the commercial LSI EGFR
Dual-Color Probe-Hyb Set (Vysis/Abbott Molecular, IL)LSI EGFR Spectrum Orange/Cep-7 Spectrum Green
in order to simultaneously visualize EGFR gene and
chromosome 7 copy number according to manufacturer’s
instructions. DAPI II (4,6-diamino-2-phenyindole-2-hy-
drochloride) was used for chromatin counterstaining.
The fluorescence signals (orange for LSI EGFR, green
for Cep-7, and blue for nuclear chromatin) were evalu-
ated under epifluorescence microscope (Olympus).
Image acquisition was done by CCD microscopy cam-
era (Olympus). Signals were evaluated by two assessors
scoring at least 60 interphase nuclei in four different
high power fields (HPF). The FISH results were scored
as follow: specimens with the ratio LSI EGFR/CEP-
7 ≥2.0 were considered as amplified; polysomic were
considered cases showing three or more CEP-7 signals
per cell in more than 20% of the evaluated cells.
In situ hybridization (ISH) for HPV-DNA detection
For HPV detection has been used an HPV ISH sistem
(Ventana Inform HPV, Tucson, AZ, USA) to detect inte-
gration or episomic status in our cases included on
Tissue Micro Array.
The commercially available Ventana kit includes the
following probes for HR-HPVs 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, e 66 (Iiform HPV family-III 16 Probe;
Ventana - Roche); and the following probes for LR-HPVs.
Statistical methods
Overall survival (OS) was calculated from date of diagno-
sis to death. Time to recurrence was calculated from date
of diagnosis to recurrence. Descriptive statistics, confi-
dence intervals [CI] and frequency counts were used to
summarize characteristics of the study population. Time
to recurrence and overall survival (OS) were calculated
using the Kaplan-Meier method. Cox proportional hazards
regression was used to investigate for prognostic factors of
time to recurrence and OS, while logistic regression ana-
lysis were used to investigate for prognostic factors of
recurrence at any time as a dichotomous variable. A mul-
tivariable model was constructed using a forward stepwise
selection procedure. A p value < 0.05 was considered sta-
tistically significant and all tests were two-sided.
Results
Patient’s characteristics
All 30 patients had early stage squamous cell penile
carcinoma, with the majority of them having classic
squamous cell penile carcinoma. Median age at diagno-
sis was 58 years (53–68) and the patients were diagnosed
between the years 2000 to 2011 and the median follow-
up was 2 years.
All patients were positive for EGFR by IHC, while 13
and 16 were respectively positive for nuclear and cytosolic
p-EGFR. No EGFR amplification was detected by FISH.
Table 1 Patients’ characteristics
Characteristics Sample population
N Number (%) median(range)
Age 58 (53–68)
T stage
T1 5
T2 24
T3/4 1
Grade
G1 9
G2 14
G3 7
Sentinal node byopsy
Yes 26
No 4
Lymphadenectomy
Yes 10
No 20
Lymphnode status*
N0 21
N1 9
Histology
Classic 23
Basaloid 6
Verroucous 1
Corpus spongiosum infiltration
Yes 18
No 12
Corpora cavernosa infiltration
Yes 7
No 23
Uretrha infiltration
Yes 1
No 29
Lymphovascular invasion
Yes 10
No 20
Surgical operation
Local excision 3
Glansectomy 1
Partial penectomy 11
Total penectomy 15
High grade HPV status
Positive 8
Negative 22
Table 1 Patients’ characteristics (Continued)
p-EGFR status
Nuclear
Positive 13
Negative 17
Cytosolic
Positive 16
Negative 14
EGFR amplification status
Amplified 0
Aneuploid 8
Euploid 17
Not evaluated 5
*As assessed by sentinal node biopsy and/or lymphadneectomy.
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Patients’ characteristics are detailed in Table 1.Staging and surgical management
All patients were treated with radical surgery. Physical
examination and biopsy for histology diagnosis were
performed before surgery in all patients. All patients
had either sentinel node biopsy or standard inguinal
lymphadenectomy or both. Often patients undergoing
inguinal lymphadenectomy, nine had N1 disease. An ab-
dominal CT scan with and without contrast excluded
pelvic lymphnode involvement in patients with N1
disease. Sentinel node biopsy was performed according
to published guidelines [4].Recurrence and survival
All patients of the sample population had a recorded
survival time. Of these, 10 patients were dead (33%) and
20 alive (66%) at the time of analysis. Penile cancer was
the cause of death of eight patients. Median survival
time was 25 months (20–50) (Figure 1). Sixteen patients
presented recurrent disease. In these patients, median time
to disease recurrence was 12.5 months (9–16.5). Grade,
lymphnode status, histology, HPV status, lymphovascular
invasion, cytosolic and nuclear p-EGFR status, corpora
cavernosa and corpus spongiosum infiltration were assessed
on univariable nad multivariable analysis as predictive of
recurrence and survival. On univariable analysis, corpora
cavernosa infiltration (OR 7.8; 95% CI = 0,8 to 75,6; P =
0,039) and positivity for cytosolic p-EGFR (OR 7.6; 95%
CI =1.49 to 50; P = 0.009 ) were predictive for recurrence
(Table 2), while only positivity for cytosolic p-EGFR
(HR =9.0; 95% CI 1.0-100; P = 0,0116) was prognostic
for poor survival. At multivariate analysis, only cytosolic
p-EGFR was associated to increased risk of recurrence
and poor survival.
Figure 1 Overall survival.
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In this retrospective analysis of 30 PSCC patients with ≤
pN1 disease undergoing surgery without perioperative
chemotherapy, tumor p-EGFR was the only significant
prognostic factor on multivariable analysis. Discriminating
expression of phosphorylated and non phosphorylated
EGFR has a biological and clinical significance in multiple
human cancers, e.g. non-small cell lung cancer and breast
cancer. In a retrospective study, conducted in 36 patients
with non small cell lung cancer, EGFR phosphorylation,
which was not associated to EGFR overexpression, was
correlated to shorter time to progression and overall sur-
vival at univariate analysis [12]. Similarly, in a series of 154
women with invasive breast cancer, EGFR and pEGFR
proteins were found in 11.3% and 35.7% of patients,Table 2 Logistic regression anlysis for disease recurrence
Characteristic Hazard ratio
(95% CI)
p-value
Univariable
Cytosolic p-EGFR
(Positive vs. Negative)
7.6 (1.49 to 50) P = 0,009
Nuclear p-EGFR
(Positive vs. Negative)
0,6 (0,1 to 2,5) P = 0,490
Corpora cavernosa
infiltration Yes vs. no
7,8 (0,8 to 75,6) P = 0,039
Corpus spongiosum
infiltration no vsyes
0,4 (0,1 to 2) P = 0,294
Age 0,9 (0,9 to 1) P = 0,807
Lymphovascular
invasion Yes vs no
2,8 (0,5 to 14,3) P = 0,190
Grade 1,7 ( 0,6 to 4,7) P = 0,295
Histology 5,9 (0,5 to 58,4) P = 0,086
HPV positive vs. negative 0,8 (0,1 to 4,2) P = 0,825
Euploid vs. Aneuploid 1,2000 0,2464 to
5,8440
P = 0,821
Multivariable
Cytosolic p-EGFR (Positive vs.
Negative)
7.6 (1.49 to 50) P = 0,009respectively, and univariate and multivariate analysis
showed that the EGFR/pEGFR phenotype was significantly
associated with poor overall survival [13]. In one study of
penile cancer patients, p-EGFR was expressed in 25% of
148 samples, but an independent prognostic impact was
not reported. A strong positive correlation of p-EGFR
with phosphorylated nuclear and cytoplasmic Akt was
identified, which is consistent with activated EGFR ac-
ting as an upstream regulator of PI3K-Akt. Specifically,
a strong negative correlation of p-EGFR was found with
PTEN protein expression, which is explained by PTEN-
mediated EGFR downregulation, and with HPV, which
suggests that distinct biological pathways are activated
in HPV negative tumors [10]. High-risk HPV is approxi-
mately found in 50% of penile carcinomas [17]. Similarly
to head an neck squamous cell carcinomas [18], high
risk HPV was found to be positively correlated to out-
come in penile carcinoma. In a series of 171 patients
with penile carcinoma, high-risk HPV DNA was detected
in 29% of the tumors. Disease-specific 5-year survival in
the high-risk HPV-negative group and high-risk HPV-
positive group was 78% and 93%, respectively. At multi-
variate analysis, the HPV status was an independent pre-
dictor for disease-specific mortality (p = 0.01) with a
hazard ratio of 0.14 (95% CI: 0.03-0.63) [6]. In our series,
presence of high-risk HPV status did not significantly affect
survival at multivariate analysis, and neither did any other
established factors such as grade and stage, while p-EGFR
was significantly related to an increased risk of recurrence
and shorter overall survival time. In our selected popula-
tion of patients with no or limited lymphnode involvement
(N0-1), eight patients (26%) died after a median followed
up of 25 months, which is concordant with 5-year cancer
specific survival probabilities between 75% and 93% for the
patients with stage cN0 disease, between 40% and 70% for
those with stage cN1 disease reported by literature [5].
Despite a clinically significant risk of disease recurrence,
adjuvant treatment is not recommended in N0-1 patients.
Risk factors allowing risk stratification are therefore espe-
cially required in this setting. Phosphorylated EGFR is
easily assessable and may be integrated along with other
histological markers of tumor aggressiveness.
In one study conducted in 110 surgical specimens
from patients with penile carcinoma, 27.2% of samples
stained positive for p53. The 5-year cancer specific sur-
vival rate for the entire study cohort was 74%, and it was
significantly lower in patients positive for p53 (51% vs.
84%, p = 0.003). At multivariable analysis, p53 showed to be
strongly related to decrease survival (HR = 3.20; p = 0.041)
[8]. In a similar fashion, EGFR appeared to be indepen-
dently predictive of enhanced risk of recurrence and de-
creased survival in our series. We chose to investigate
the role of EGFR in a specific and homogeneous subset
of PC patients – those with N0-1 disease-, who are
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clinically relevant risk of recurrence. Limitations of our
study include the small number of patients, the lack of
study design and of prespecified variable for multivari-
able analysis and the fact that tumor samples were not
prospectively collected under controlled conditions,
which can influence results of IHC. Hence, external val-
idation and multivariable analyses including more vari-
ables such as those included in the nomogram may
improve the confidence in the independent impact of p-
EGFR [5]. Comprehensive tumor genomic analysis is
also warranted. Detection of p-EGFR could suggest not
only the need for adjuvant therapy, even in patients with
N0 or N1 disease, but may potentially be predictive of
benefit from the the use of anti-EGFR drugs. Indeed one
case report has described the activity of panitumumab
as second-line therapy in penile cancer, which exhibited
amplified EGFR with no K-Ras mutations [19]. Of note,
we recently reported that mutations commonly found in
patients with non-small-cell lung cancer were not
detected in penile cancer patients [20], which shows
that the biological mechanism underlying EGFR activa-
tion remains to be fully explored.
Conclusions
Our hypothesis-generating study showed that p-EGFR
can be a powerful tool for prognosis discrimination of
penile cancer patients with limited or no lymphnode
involvement. Our study is the first to show such a rela-
tionship in a selected population not normally candi-
date for adjuvant therapy. The clinically relevant risk of
disease recurrence strongly highlights the need for fur-
ther stratification factors in such selected population of
surgical PC patients. Our findings may have a huge
impact as not only could they select N0-1 patients in
need for adjuvant therapy, but could also select patients
responsive to anti-EGFR therapy. This fascinating hy-
pothesis requires external validation in a larger dataset,
and integration of p-EGFR with classic prognostic fac-
tors and other histology markers should be pursued to
establish optimal adjuvant therapy for these patients.
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